Taiwan Cell Therapy Companies and Pipelines, Including Cell-Derived Exosomes
As of October 22, 2026, this table verifies cell therapy or cell-derived exosome programs at nine Taiwan companies, selecting one publicly staged product or program per company. [1] [2] [3] [4] [5] [6] [7] [8] [9]
REGENECYTE is FDA-approved for unrelated-donor hematopoietic progenitor cell transplantation; the other selected programs retain their disclosed clinical or IND-preparation status, with LT6001 identified as an exosome program rather than a living-cell product. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11]
| Company | Ticker | Product / pipeline | Indication | Latest verified stage | Stage source and date | Most recent catalyst |
|---|---|---|---|---|---|---|
| MEDIGEN Company source | 3176 | Allogeneic Magicell-NK | Adjuvant treatment after surgery for pancreatic ductal adenocarcinoma or cholangiocarcinoma, with chemotherapy | Phase I/II; first patient enrolled June 29, 2026 | 2026-06-30 Stage source 完成首位受試者收案 | On June 30, 2026, the company announced first patient enrollment in the allogeneic Magicell-NK trial on the preceding day. 2026-06-30 Source 已於2026年6月29日正式啟動人體臨床試驗 |
| StemCyte Company source | 4178 | REGENECYTE (HPC, Cord Blood) | Hematopoietic and immune reconstitution in unrelated-donor transplantation for inherited, acquired or myeloablative-treatment-related hematopoietic disorders | U.S. FDA approval granted November 20, 2024 | 2024-11-20 Stage source November 20, 2024 Approval Letter | On September 30, 2026, the company announced a Taiwan REGENECYTE NDA filed by its Taiwan operation under authorization from StemCyte, Inc.; review remains pending. 2026-09-30 Source 再生醫療製劑查驗登記 |
| PharmaEssentia Company source | 6446 | KRAS TCR-T | Solid tumors | IND-enabling; company plans an IND in 2027 | 2026-08-25 Stage source Planned IND in 2027 | The presentation schedules the KRAS TCR-T IND for 2027; submission or authorization is not established. 2026-08-25 Source Planned IND in 2027 |
| Lumosa Therapeutics Company source | 6535 | LT6001 / CS026 (cell-derived exosomes, not a living-cell product) | Neurological diseases | IND/IIT planning; a formal Phase 1 start is not established | 2026-05-15 Stage source LT-6001 神經學疾病 外泌體 | — |
| Ever Supreme Company source | 6712 | CAR001 | Malignant / solid tumors | Phase IIa trial initiated | 2026-07-01 Stage source 正式啟動Phase IIa臨床試驗 | — |
| UnicoCell Company source | 6794 | ELIXCYTE-OA (allogeneic adipose-derived mesenchymal stem cells) | Knee osteoarthritis | Phase III; last patient enrolled | 2026-10-01 Stage source 已分別完成第三期臨床試驗收案 | On October 1, 2026, the company announced an export-only drug permit for UC-hADSC; this does not establish Taiwan marketing approval for knee osteoarthritis. 2026-10-01 Source UC-hADSC取得外銷專用藥品許可證 |
| Pell Bio-Med Technology Company source | 6949 | PL001 (CD19 CAR-T) | Relapsed or refractory B-cell lymphoma | Phase 1/2 (registered study); active, not recruiting | 2026-10-09 Stage source ACTIVE_NOT_RECRUITING | The registered estimated primary completion date is December 31, 2026; no completed result is inferred. 2026-10-09 Source 2026-12-31 |
| Hexun Biosciences Company source | 6986 | HeXell-2020 (mesenchymal stem cells) | Stable coronary artery disease | Phase I/IIa; recruiting | 2026-09-29 Stage source A Phase I/IIa Study | The registered estimated primary completion date is December 31, 2028; this is a planned date, not a completed result. 2026-09-29 Source 2028-12-31 |
| BIONET TX Corp. Company source | 7808 | BU01 (umbilical cord mesenchymal stem cells) | Pulmonary fibrosis | Phase II | 2026-10-22 Stage source 臍帶間質幹細胞新藥BU-01治療肺部纖維化跨入人體臨床二期 | — |
Scope and public-document limits
This is a verified selection, not an exhaustive Taiwan census; exosomes are identified separately. Estimated registry dates, planned INDs, a Taiwan NDA filing and an export-only permit retain their own scope and are not converted into completed trial results or Taiwan indication-specific marketing approvals.